🔗 Share this article

Given that the US continues making historic revisions to its immunization guidelines, a particular individual has emerged unexpectedly: Høeg, a US-based physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations throughout the global health crisis and has concentrated on possible fatalities after COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Program

Public health authorities planned to reveal radical revisions to the pediatric immunization program in December, bringing the US with Denmark’s vaccine program, according to reports – a significant shift that would put the US at odds with many the international standard with no evidence for benefit. This reveal has been postponed until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to lead the office this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics divisions as Høeg and Dr. Prasad solidify control at the agency – and it points to a increased emphasis upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting some childhood immunization guidelines in the US in order to be more in line with the Danish model, a nation with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

To date public appearances, she has kept her attention on immunizations – traditionally the responsibility of Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Concerns Over Background

The appointee has no obvious track record in drug development, oversight or administrative roles, which has been typical for former directors of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, said Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in running a major agency. She is not an expert in industry regulation.”

Former directors of the center would “understand regulatory frameworks and the research of drug development”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that former directors who headed CBER have had.”

This division has an immense portfolio at the FDA, the former commissioner stated.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office clears thousands of generic drugs. There is also a biosimilars division, non-prescription drug unit and so forth, and all of those must be managed,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial administrative aspect to the position, which manages in excess of 5,000 staff members. “It is a massive administrative position, if you execute it properly,” Woodcock said.

Agency Reaction and Disputed Policies

Regarding inquiries about Dr. Høeg's qualifications and whether this appointment represents increased cooperation among regulatory chiefs on vaccines, a representative responded that the “inquiries are based on incorrect premises”.

“Her resume aligns with the functions of her job,” the representative explained, noting the period Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a disputed expedited drug-approval program that allegedly worried her former heads. “How are these drugs being picked for this fast-track system? Who is making the calls?” Dr. Howard said. “There is a lot of confidentiality happening at the FDA right now.”

In general, he stated, “the FDA appears to be shifting towards laxer oversight of all drugs, aside from immunizations.”

Documented Track Record on Immunizations

Regarding vaccines, Høeg has a more documented, if concerning, past, critics have noted. She published a analysis using unverified volunteer-provided data to determine the frequency of heart inflammation following COVID-19 immunization. She advised the Florida surgeon general Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccinations are pose a greater threat than they are.

Among her “desired changes” for the incoming government featured revising rules for new vaccines and ending “optional” immunizations, she remarked post-election on a online show. At the FDA, Høeg has reportedly floated the idea of barring young men from getting COVID-19 vaccinations.

“She’s an thorough ideologue who commences with her beliefs and reverse-engineers to retrofit the science in a extremely misleading, untruthful fashion,” Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined other dissenters, {like|